Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2225 studies found for:    Mexico
Show Display Options
Rank Status Study
1 Recruiting Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis
Condition: Arthritis, Rheumatoid
Intervention: Drug: CP-690,550
2 Recruiting Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo;   Drug: Linagliptin
3 Recruiting Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Vildagliptin;   Drug: Insulin;   Drug: Placebo
4 Completed
Has Results
Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome
Conditions: Diabetes Mellitus, Type 2;   Acute Coronary Syndrome
Interventions: Drug: Alogliptin;   Drug: Placebo
5 Completed A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Aleglitazar;   Drug: Placebo
6 Completed An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: erlotinib [Tarceva]
7 Completed Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy
Conditions: Prostate Cancer;   Osteoporosis;   Fractures
Intervention: Drug: Toremifene Citrate
8 Terminated
Has Results
Study to Evaluate the Safety and Efficacy of Pradaxar for the Prevention of Venous Thromboembolism in the Mexican Population Undergoing Elective Total Hip or Knee Replacement Surgery
Conditions: Thromboembolism;   Arthroplasty, Replacement, Hip
Intervention:
9 Recruiting Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities
Condition: Cardiovascular Disease
Interventions: Drug: Febuxostat;   Drug: Allopurinol
10 Active, not recruiting A Study of RoActemra/Actemra (Tocilizumab) in Comparison to Etanercept in Patients With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors
Condition: Cardiovascular Disease, Rheumatoid Arthritis
Interventions: Drug: etanercept;   Drug: tocilizumab [RoActemra/Actemra]
11 Recruiting Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma
Condition: Severe IgE-mediated Asthma
Interventions: Drug: Omalizumab;   Drug: Budesonide;   Drug: Formoterol
12 Terminated Phase III Acute Coronary Syndrome
Condition: Acute Coronary Syndrome
Interventions: Drug: Apixaban;   Drug: Placebo
13 Completed A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease
Condition: Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)
Interventions: Other: Background care;   Drug: dalcetrapib;   Drug: Placebo
14 Recruiting Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults
Condition: Influenza
Intervention: Drug: favipiravir
15 Completed
Has Results
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
Condition: Venous Thrombosis
Interventions: Drug: Apixaban;   Drug: Placebo
16 Recruiting Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Exenatide Once Weekly;   Drug: Placebo
17 Recruiting ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)
Condition: Acute Coronary Syndrome
Interventions: Drug: alirocumab SAR236553 (REGN727);   Other: placebo
18 Completed Study Evaluating How Patients With Acute Coronary Syndrome Are Managed During 2 Years After Discharge
Conditions: ACS;   Acute Coronary Syndrome;   Myocardial Infarction;   Unstable Angina;   Coronary Artery Disease
Intervention:
19 Recruiting A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Conditions: Breast Cancer;   Neoplasm Metastasis
Interventions: Other: Standard supportive care (packed RBC transfusion);   Drug: epoetin alfa + packed RBC transfusion
20 Active, not recruiting Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010);   Drug: placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years